Back to today’s briefing

Story perspectives

FDA Reapproves Blenrep, Forecasts $4 Billion Sales in Myeloma Market

10/24/2025

30 3

Summary

Story summary

On October 23, 2025, the U.S. FDA approved GlaxoSmithKline's Blenrep with bortezomib and dexamethasone for relapsed multiple myeloma, returning the drug to market after a 2022 withdrawal due to trial underperformance.
The approval follows a July advisory panel's recommendation against Blenrep.
GlaxoSmithKline projects over $4 billion in peak sales as the multiple myeloma market is expected to reach $45 billion by 2032.

1 of 1

Story summary

On October 23, 2025, the U.S. FDA approved GlaxoSmithKline's Blenrep with bortezomib and dexamethasone for relapsed multiple myeloma, returning the drug to market after a 2022 withdrawal due to trial underperformance.
The approval follows a July advisory panel's recommendation against Blenrep.
GlaxoSmithKline projects over $4 billion in peak sales as the multiple myeloma market is expected to reach $45 billion by 2032.